Abbreviations: HIF-1α, hypoxia inducible factor-1α; STAT3, signal transducer and activator of transcription 3; VHL, von Hippel-Lindau Abstract Hypoxia-inducible factor 1α (HIF-1α) is rapidly degraded by the ubiquitin-proteasome pathway under normoxic conditions. Ubiquitination of HIF-1α is mediated by interaction with von Hippel-Lindau tumor suppressor protein (pVHL). In our previous report, we found that hypoxia-induced active signal transducer and activator of transcription3 (STAT3) accelerated the accumulation of HIF-1α protein and prolonged its half-life in solid tumor cells. However, its specific mechanisms are not fully understood. Thus, we examined the role of STAT3 in the mechanism of pVHL-mediated HIF-1α stability. We found that STAT3 interacts with C-terminal domain of HIF-1α and stabilizes HIF-1α by inhibition of pVHL binding to HIF-1α. The binding between HIF-1α and pVHL, negative regulator of HIF-1α stability, was interfered dose-dependently by overexpressed constitutive active STAT3. Moreover, we found that the enhanced HIF-1α protein levels by active STAT3 are due to decrease of poly-ubiquitination of HIF-1α protein via inhibition of interaction between pVHL and HIF-1α. Taken together, our results suggest that STAT3 decreases the pVHL-mediated ubiquitination of HIF-1α through competition with pVHL for binding to HIF-1 α, and then stabilizes HIF-1α protein levels.
Introduction
Hypoxia is a critical condition to initiate many adaptive responses in pathological and physiological processes (Bunn and Poyton, 1996) . In many solid tumors, hypoxia is a common feature, and closely related with malignant progression of cancer cells (Hockel and Vaupel, 2001; Joung et al, 2005) . Under hypoxic conditions, the diverse genes involved in angiogenesis, erythropoiesis and energy metabolisms are transcriptionally up-regulated by the heterodimeric hypoxia inducible factor-1 (HIF-1) (Semenza, 2001; Wenger, 2002) . The α subunit of HIF-1 is the hypoxia-responsive component of the dimer, while HIF-1β is expressed constitutively (Kallio et al., 1999) .
Under normoxic conditions, HIF-1α is rapidly degraded by the ubiquitin-proteasome pathway (Ohh et al., 2000) . Ubiquitination of HIF-1α is mediated by interaction with von Hippel-Lindau tumor suppressor protein (pVHL) (Kim et al, 2008) . HIF-1α is targeted for VHL E3 ligase complex by proline hydroxylation of oxygen-dependent degradation (ODD) domain (Semenza, 2001; Safran and Kaelin, 2003) . Hydroxylated HIF-1α is associated with pVHL which has E3 ubiquitin ligase activity and is rapidly degraded by ubiquitin-proteasome pathway (Ivan et al., 2001) . Prolyl hydroxylase (PHD) utilize oxygen as a substrate and iron, as a cofactor to hydroxylate the proline residues on HIF-1α (Bruick and McKnight, 2001; Berra et al., 2006) . However, under hypoxic conditions, HIF-1α is stabilized due to inhibition of HIF-1α modifying enzymes by low oxygen levels.
Signal transducer and activators of transcription (STAT) proteins play roles in various signaling pathways, including cytokine, growth factor, and hormone signaling (Horvath, 2000) . STATs are activated by tyrosine phosphorylation, and phosphorylated STAT forms hetero-or homo-dimer, then translocate to the nucleus (Darnell, 1997) . Several constitutively activated STATs have been observed in large wide number of human cancer cell lines and primary tumors (Bowman, 2000; Song, 2000) . STAT3 proteins play a role in tumorigenesis through up-regulation of genes encoding apoptosis inhibitors, cell-cycle regulators, and inducers of angiogenesis (Sinibaldi et al., 2000; Niu et al., 2002) . Aberrant activation of STAT3 is also commonly observed in solid tumors and strongly associated with tumor development and progression Song and Grandis, 2000; Schaefer et al., 2002) . In our previous report, we found that hypoxia-induced active STAT3 accelerated the accumulation of HIF-1α protein and prolonged its half-life in solid tumor cells (Jung et al., 2005) . However, its specific mechanisms are not fully understood. Thus, in this study, we investigated the mechanisms whereby active STAT3 stabilizes and increases HIF-1α protein levels by focusing on pVHL-mediated HIF-1α degradation.
Materials and Methods
Cell culture COS7 (monkey kidney cell lines) cells and Caki-I (human renal carcinoma) cells were purchased from ATCC and maintained in DMEM supplemented with 10% FBS (Life Technologies, Gaithersburg, MD) and 1% antibiotics. For induction of HIF-1α protein, cells were treated with 20 μM with MG132 (Calbiochem, CA) after transfection with HA-GFP-HIF-1α.
Plasmid constructs and transient transfection
Wild type of HA-GFP-HIF-1α, series of domain deletion of HIF-1α constructs, and HA-ubiquitin were generously provided by Dr. Jong Wan Park (Seoul National University, Korea). The pCR3-VHL-HA was generously provided by Dr. Hong-Duk Youn (Seoul National University, Korea). The constitutive active form of STAT3 (STAT3 CA) was generously provided by Dr. Hyun-Gyu Lee (Seoul National University, Korea). Cells were transfected with LipofectAMINE reagent (Invitrogen, San Diego, CA) according to the manufacturer's directions.
Coimmunoprecipitation, immunobloting
After 24 h of transfection into COS7 cells, 20 μM of MG132 were treated for 3 h and lysed on ice with lysis buffer [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% NP-40 and 1 mM PMSF]. Whole cell lysates were immunoprecipitated using suitable antibodies and protein G-Sepharose (Pierce) at 4 o C for 2 h. Binding and washing were performed in the same buffer, except the NaCl concentration was diluted four fold. Immunoprecipitates were separated by SDS-PAGE, electrotransferred to nitrocellulose membrane, and immunoblotted with appropriate antibodies. Anti-HIF-1α was provided by Dr. Jong Wan Park (Seoul National University); anti-phospho STAT3, anti-β-actin, anti-ubiquitin, anti-GFP were purchased from Santa Cruz Biotechnology; anti-pVHL, anti-HA were purchased from BD Transduction Laboratory.
Proteasome inhibition and in vivo ubiquitination assay
COS7 cells or Caki-I cells were transiently transfected with mammalian expression vectors for HA-GFP-HIF-1α, HA-pVHL, and HA-Ub. After 24 h of incubation, cells were treated with 20 μM of MG132 for a further 5 h. Cells were lysed with lysis buffer and immunoprecipitated with anti-HIF-1α antibody. Immunoprecipitated cell lysates were subjected to 6% SDS-PAGE, and ubiquitinylated HIF-1α was detected with anti-ubiquitin antibody.
Statistical analysis
Results are presented as means ± S.E.M. Data are analyzed by using Student's t test. Differences were considered statistically significant at a P value of ＜ 0.05
Result

STAT3 interacts with HIF-1α and increases HIF-1α protein levels
To confirm the involvement of hypoxia-induced active STAT3 in HIF-1α stabilization, we first examined the physical interaction between constitutive active STAT3 and HA-GFP-HIF-1α. The interaction between HIF-1α and STAT3 in vivo was confirmed by coimmunoprecipitation assays. When the overexpressed HA-GFP-HIF-1α in COS7 cells or Caki-I cells (data not shown) was stabilized by MG132 under normoxic conditions, the overexpressed constitutive active STAT3 was immunoprecipitated ( Figure 1A) . Also, to examine whether active STAT3 increases the HIF-1α protein stability, COS7 cells were transiently transfected with constitutive active STAT3 in a dose dependent manner. As shown in Figure 1C , along with increasing amount of constitutive active STAT3, the protein levels of HA-GFP-HIF-1α increased gradually. This result indicates that STAT3 is involved in HIF-1α stabilization.
Next, to investigate which domain of HIF-1α interacts with STAT3, we performed the coimmunoprecipitation assay using each series of deletion constructs of HIF-1α. When the overexpressed each series of deletion constructs of HIF-1α in COS7 cells was stabilized by MG132 under normoxic conditions, the overexpressed C-terminal domain of HIF-1α was immunoprecipitated by the overexpressed constitutive active STAT3 (Figure 2) . It was not found that the overexpressed other deletion domains of HIF-1α, N-termini and ODD were not precipitated by active STAT3. 
STAT3 competes with pVHL for binding to HIF-1α
It is well known that pVHL plays an important role in hypoxia-induced HIF-1α stability via direct interaction. HIF-1α protein levels are mainly regulated by oxygen-dependent pVHL-mediated ubiquitination-proteasome degradation pathway (Ivan et al, 2001; Safran and Kaelin, 2003) . Therefore, we investigated whether STAT3 increase HIF-1α protein levels by inhibiting pVHL-mediated degradation. As shown in Figure 3A , constitutive active STAT3 was co-expressed in a dose dependent manner with the wild type of pVHL and HIF-1α in COS7 cells. Along with increasing amount of overexpressed constitutive active STAT3, the bindings of overexpressed pVHL to overexpressed HIF-1α were decreased gradually ( Figure 3A ).
STAT3 decrease poly-ubiquitination of HIF-1α via inhibition of VHL binding
The overexpression of constitutive active STAT3 abolished the interaction between HIF-1α and pVHL in a dose dependent manner ( Figure 3A) . Thus, we next examined whether STAT3 is involved in the pVHL-mediated ubiquitination of HIF-1α. HA-ubiquitin, HA-pVHL and HA-GFP-HIF-1α were co-expressed with or without overexpression of constitutive active STAT3 in COS7 cells ( Figure 4A Figure 4A ). The poly-ubiquitination of HA-GFP-HIF-1α was significantly reduced in cells overexpressed with constitutive active STAT3 ( Figure 4A , lane 2) and the overexpressed HA-GFP-HIF-1α protein levels were more enhanced in cells with overexpressed constitutive active STAT3 ( Figure  4C ). This result indicates that STAT3 blocks pVHL-mediated ubiquitination of HA-GFP-HIF-1α, because the binding of HA-pVHL to the HA-GFP-HIF-1α was significantly reduced in cells overexpressed with constitutive active STAT3 ( Figure 4B ). Taken our results, we suggest that STAT3 enhances HIF-1α stability through inhibition of the pVHLmediated ubiquitination of HIF-1α.
Discussion
STAT3 is considered to be an oncogene since it cause the activation of cyclin D1, c-myc, and bcl-xL expression, and also is involved in promotion of cell-cycle progression, cellular transformation, and the prevention of apoptosis (Darnell, 1997; Bowman et al., 2000) . In our previous report, we have demonstrated that STAT3 is a pivotal regulator of HIF-1-mediated VEGF expression in hypoxic solid tumor cells (Jung et al., 2005) . Thus, STAT3 is considered to be an oncogenic inducer in solid tumor as well as HIF-1. Also, we found that hypoxia-induced active STAT3 accelerated the accumulation of HIF-1α protein and prolonged its half-life in solid tumor cells (Jung et al., 2005) . However, its specific mechanisms are not fully understood.
In this study, we investigated the role of STAT3 in the mechanism of pVHL-mediated HIF-1α stability. We found that STAT3 interacts with the C-terminal domain of HIF-1α and stabilizes HIF-1α by competition with pVHL for binding to HIF-1α. The inter-action between HIF-1α and negative regulator of HIF-1α stability, pVHL was interfered by dosedependently overexpressed constitutive active STAT3. Moreover, we found that the enhanced HIF-1α protein levels by active STAT3 are due to decrease of poly-ubiquitination of HIF-1α protein via inhibition of interaction between pVHL and HIF-1α. Taken together, our results suggest that STAT3 decreases the pVHL-mediated ubiquitination of HIF-1α through competition with pVHL for binding to HIF-1α, and then stabilizes HIF-1α protein levels.
Under normoxic conditions, HIF-1α is rapidly degraded by the ubiquitin-proteasome pathway (Ohh et al., 2000) . Ubiquitination of HIF-1α is mediated by interaction with pVHL. HIF-1α is targeted for VHL E3 ligase complex by proline hydroxylation of oxygen-dependent degradation (ODD) domain (Semenza, 2001; Safran and Kaelin, 2003) . Hydroxylated HIF-1α is associated with pVHL which has E3 ubiquitin ligase activity and is rapidly degraded by the ubiquitin-proteasome pathway (Ivan et al., 2001) . The ODD domain of HIF-1α is mainly critical domain for regulation of HIF-1α stabilization, because it is reported that ODD domain is interacted with pVHL in HIF-1α degradation by ubiquitin-proteasome pathway. Thus, it is conceivable that the binding of STAT3 to HIF-1α occurs in the ODD domain of HIF-1α and consequently, the inhibition of pVHL binding to HIF-1α by competent binding of STAT3 occurs in the ODD domain. However, interestingly, our result showed that STAT3 interacts with HIF-1α in the C-terminal region, the very next region of ODD domain of HIF-1α ( Figure  2 ). Since STAT3 protein has a high molecular weight and forms hetero or homo-dimer structure in its active state, there is the possibility that the heavy and complicated structured STAT3 protein can interfere with the binding of pVHL to HIF-1α. It still remains to be solved by in vitro assays whether the interaction between STAT3 and HIF-1α is direct or indirect.
In conclusion, the results of this study demonstrate that active STAT3 enhances HIF-1α protein stability through inhibition of pVHL binding to the HIF-1α and pVHL-mediated ubiquitinantion of HIF-1α. In addition, it is suggested that STAT3 is a superior target for the development of anticancer drugs which has focused on targeting HIF-1α.
